

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.



STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE, 2013

PART I (Rs. in lakhs)

PARTICULARS	3 months ended 30.6.2013	3 months ended 31.3.2013	3 months ended 30.6.2012	Year ended 31.3.2013
	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations				
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,290	5,634	5,472	21,621
(b) Other Operating Income	128	207	107	543
Total Income from Operations (Net)	6,418	5,841	5,579	22,164
2. Expenses				
(a) Cost of Materials Consumed	1,910	1,212	1,355	5,479
(b) Purchases of Stock-in-Trade	449	425	359	1,880
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(350)	441	180	285
(d) Employee Benefits Expense	1,472	1,351	1,227	5,520
(e) Depreciation and Amortisation Expense	254	253	237	987
(f) Other Expenses	2,095	1,690	1,802	7,393
Total Expenses	5,830	5,372	5,160	21,544
3. Profit from Operations before Other Income Finance Costs and Exceptional Items	588	469	419	620
4. Other Income	84	90	34	178
5. Profit from Ordinary Activities before Finance Costs and Exceptional Items	672	559	453	798
6. Finance Costs	161	206	168	744
7. Profit from Ordinary Activities after Finance Costs but before Exceptional Items	511	353	285	54
8. Exceptional Items	6,426	-	-	-
9. Profit from Ordinary Activities before Tax	6,937	353	285	54
10. Tax Expense/(Credit) (including Deferred Tax)	1,468	(387)	6	(387)
11. Net Profit for the period	5,469	740	279	441
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				6,300
14. Earnings per Share (of Rs. 8 each) (not annualised):				
(a) Basic	33.07	4.48	1.69	2.67
(b) Diluted	33.07	4.48	1.69	2.67

PART II

Select Information for the Quarter ended 30th June, 2013

PARTICULARS	3 months ended 30.6.2013	3 months ended 31.3.2013	3 months ended 30.6.2012	Year ended 31.3.2013
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	7,196,344	7,196,344	7,754,293	7,196,344
- Percentage of Shareholding	43.52	43.52	46.90	43.52
2. Promoters and Promoter Group Shareholding				
(a) Pledged/Encumbered				
- Number of Shares	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-
(b) Non-Encumbered				
- Number of Shares	9,338,897	9,338,897	8,780,948	9,338,897
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	56.48	56.48	53.10	56.48

PARTICULARS	3 months ended 30.6.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	3
Disposed of during the quarter	3
Remaining unsolved at the end of the quarter	-

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 26th July, 2013.
- The results for the quarter ended 30th June, 2013 have been subjected to limited review by the statutory auditors of the company.
- The figures for the quarter ended 31st March, 2013 are the balancing figures between the audited financial results for the year ended 31st March, 2013 and the published unaudited financial results for the nine months ended 31st December, 2012.
- The company is exclusively engaged in the pharmaceuticals segment.
- Exceptional Items comprise of profit of Rs. 6,184 lakhs on sale of a portion of leasehold land and building thereon and the company's share of interest income of Rs. 242 lakhs earned on the sale consideration deposited by the buyer in an escrow account, jointly held in the name of the company and the buyer, till the execution of the sale deed. The amount of sale consideration and the company's share of interest income lying in the escrow account has been transferred to the company on 6th June, 2013, the date of execution of the sale deed.
- Subsequent to the pre-approval inspection of the company's API facility at Navi Mumbai and formulation facility at Ankleshwar by USFDA, the company has received a notice of non-compliance from USFDA during the quarter. The company has duly responded to the said notice. However, there is no immediate business impact of this event as the company does not have any exports to USA.
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

Ajit Singh Chouhan
Managing Director

Mumbai, 26th July, 2013

